<DOC>
	<DOCNO>NCT02636699</DOCNO>
	<brief_summary>The PEPITES study evaluate efficacy safety Viaskin Peanut 250 µg peanut protein induce desensitization peanut peanut-allergic child 4 11 year age 12-month treatment epicutaneous immunotherapy ( EPIT ) .</brief_summary>
	<brief_title>Efficacy Safety Viaskin Peanut Children With Immunoglobulin E ( IgE ) -Mediated Peanut Allergy</brief_title>
	<detailed_description />
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Peanut Hypersensitivity</mesh_term>
	<criteria>Main 1 . Male female child age 4 11 year ; 2 . Physiciandiagnosis peanut allergy child well document medical history IgEmediated symptom ingestion peanut currently follow strict peanutfree diet , without physician diagnosis ; 3 . Peanutspecific IgE level ( ImmunoCAP system ) &gt; 0.7 kU/L ; 4 . Positive peanut skin prick test ( SPT ) large wheal diameter : ≥6 mm child 4 5 year age Visit 1 , ≥8 mm child 6 year Visit 1 ; 5 . Positive DBPCFC ≤300 mg peanut protein . Main 1 . History severe anaphylaxis peanut follow symptom : hypotension , hypoxia , neurological compromise ( collapse , loss consciousness incontinence ) ; 2 . Generalized dermatologic disease 3 . Diagnosis mast cell disorder , include mastocytosis uricaria pigmentosa well hereditary idiopathic angioedema ; 4 . Diagnosis asthma fulfills follow criterion : Uncontrolled persistent asthma define National Asthma Education Prevention Program Asthma guideline 2007 Global Initiative Asthma guideline 2015 , Asthma treat either high daily high dose inhale corticosteroid combination therapy medium high daily dose inhaled corticosteroid long act inhale β2 agonist combination therapy high daily dose inhaled corticosteroid long act inhale β2 agonist . Asthmatic subject treat medium daily dose inhaled corticosteroid eligible . Intermittent asthmatic subject require intermittent use inhaled corticosteroid rescue also eligible , Two systemic corticosteroid course asthma past year 1 oral corticosteroid course asthma within 3 month prior Visit 1 , screen period , Prior intubation/mechanical ventilation asthma within 1 year prior Visit 1 , screen ; 5 . Receiving βblocking agent , angiotensinconverting enzyme inhibitor , angiotensinreceptor blocker , calcium channel blocker tricyclic antidepressant therapy ; 6 . Received antitumor necrosis factor drug antiIgE drug ( omalizumab ) biologic immunomodulatory therapy within 1 year prior Visit 1 , screen period study participation ; 7 . Use systemic longacting corticosteroid within 12 week prior Visit 1 and/or use systemic shortacting corticosteroid within 4 week prior Visit 1 screening ; 8 . Prior concomitant history immunotherapy food ; 9 . Receiving plan receive aeroallergen immunotherapy participation study . Aeroallergen immunotherapy must discontinue time Visit 1 ; 10 . Any disorder epinephrine contraindicate coronary artery disease , uncontrolled hypertension , serious ventricular arrhythmia .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>